Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity.

Armirotti A, Tomati V, Matthes E, Veit G, Cholon DM, Phuan PW, Braccia C, Guidone D, Gentzsch M, Lukacs GL, Verkman AS, Galietta LJV, Hanrahan JW, Pedemonte N.

Sci Rep. 2019 Jul 16;9(1):10310. doi: 10.1038/s41598-019-46639-1.

2.

Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia.

Tomati V, Caci E, Ferrera L, Pesce E, Sondo E, Cholon DM, Quinney NL, Boyles SE, Armirotti A, Ravazzolo R, Galietta LJ, Gentzsch M, Pedemonte N.

JCI Insight. 2019 Apr 4;4(7). pii: 128935. doi: 10.1172/jci.insight.128935. eCollection 2019 Apr 4. No abstract available.

3.

The cystic fibrosis airway milieu enhances rescue of F508del in a pre-clinical model.

Gentzsch M, Cholon DM, Quinney NL, Boyles SE, Martino MEB, Ribeiro CMP.

Eur Respir J. 2018 Dec 20;52(6). pii: 1801133. doi: 10.1183/13993003.01133-2018. Print 2018 Dec. No abstract available.

PMID:
30287473
4.

Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia.

Tomati V, Caci E, Ferrera L, Pesce E, Sondo E, Cholon DM, Quinney NL, Boyles SE, Armirotti A, Ravazzolo R, Galietta LJ, Gentzsch M, Pedemonte N.

JCI Insight. 2018 Feb 8;3(3). pii: 98699. doi: 10.1172/jci.insight.98699. eCollection 2018 Feb 8. Erratum in: JCI Insight. 2019 Apr 4;4(7):.

5.

Recent progress in translational cystic fibrosis research using precision medicine strategies.

Cholon DM, Gentzsch M.

J Cyst Fibros. 2018 Mar;17(2S):S52-S60. doi: 10.1016/j.jcf.2017.09.005. Epub 2017 Oct 4. Review.

6.

Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation.

Cholon DM, Esther CR Jr, Gentzsch M.

Expert Rev Precis Med Drug Dev. 2016;1(3):235-243. Epub 2016 Apr 22.

7.

Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.

Gentzsch M, Ren HY, Houck SA, Quinney NL, Cholon DM, Sopha P, Chaudhry IG, Das J, Dokholyan NV, Randell SH, Cyr DM.

Am J Physiol Lung Cell Mol Physiol. 2016 Sep 1;311(3):L550-9. doi: 10.1152/ajplung.00186.2016. Epub 2016 Jul 8.

8.

Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.

Cholon DM, Quinney NL, Fulcher ML, Esther CR Jr, Das J, Dokholyan NV, Randell SH, Boucher RC, Gentzsch M.

Sci Transl Med. 2014 Jul 23;6(246):246ra96. doi: 10.1126/scitranslmed.3008680.

9.

Passive immunization with a polyclonal antiserum to the hemoglobin receptor of Haemophilus ducreyi confers protection against a homologous challenge in the experimental swine model of chancroid.

Leduc I, Fusco WG, Choudhary N, Routh PA, Cholon DM, Hobbs MM, Almond GW, Orndorff PE, Elkins C.

Infect Immun. 2011 Aug;79(8):3168-77. doi: 10.1128/IAI.00017-11. Epub 2011 Jun 6.

10.

Immunization with the Haemophilus ducreyi hemoglobin receptor HgbA with adjuvant monophosphoryl lipid A protects swine from a homologous but not a heterologous challenge.

Fusco WG, Afonina G, Nepluev I, Cholon DM, Choudhary N, Routh PA, Almond GW, Orndorff PE, Staats H, Hobbs MM, Leduc I, Elkins C.

Infect Immun. 2010 Sep;78(9):3763-72. doi: 10.1128/IAI.00217-10. Epub 2010 Jun 28.

11.

Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures.

Cholon DM, O'Neal WK, Randell SH, Riordan JR, Gentzsch M.

Am J Physiol Lung Cell Mol Physiol. 2010 Mar;298(3):L304-14. doi: 10.1152/ajplung.00016.2009. Epub 2009 Dec 11.

12.

Serial isolates of persistent Haemophilus influenzae in patients with chronic obstructive pulmonary disease express diminishing quantities of the HMW1 and HMW2 adhesins.

Cholon DM, Cutter D, Richardson SK, Sethi S, Murphy TF, Look DC, St Geme JW 3rd.

Infect Immun. 2008 Oct;76(10):4463-8. doi: 10.1128/IAI.00499-08. Epub 2008 Aug 4.

Supplemental Content

Loading ...
Support Center